N@N

Opexa to Present at the Rodman & Renshaw 12th Annual Healthcare Conference on September 14, 2010

_{//health-fitness.news-articles.net/content/2010/ .. -healthcare-conference-on-september-14-2010.html}
^{Published in Health and Fitness on Wednesday, September 8th 2010 at 6:51 GMT by Market Wire}  

THE WOODLANDS, Texas--([ BUSINESS WIRE ])--Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing Tovaxin^®, a personalized T-cell immunotherapy for multiple sclerosis (MS), today announced that Neil K. Warma, Opexaa™s President and Chief Executive Officer, will deliver a corporate presentation at the Rodman & Renshaw 12^th Annual Healthcare Conference. The conference will be held September 12-15, 2010 at the New York Palace Hotel in New York City.

Opexaa™s presentation will occur at 4:30 p.m. (EDT) on Tuesday, September 14, 2010 in the Hubbard Salon (5^th Floor) of the New York Palace Hotel and will include an overview of the Companya™s ongoing clinical development program for Tovaxin, the Companya™s lead therapy for MS. The presentation will be webcasted and the link to access the audio webcast and presentation will be available at the Investor Relations page of the Companya™s website at [ www.opexatherapeutics.com ].

About Opexa

Opexa Therapeutics, Inc. is dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases. The Companya™s leading therapy, Tovaxin®, is a personalized cellular immunotherapy treatment that is in clinical development for multiple sclerosis (MS). Tovaxin is derived from T-cells isolated from peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin and, thereby, reduces the risk of relapse over time.

Opexa completed its 150 patient Tovaxin for Early Relapsing Multiple Sclerosis (TERMS) Phase 2b clinical study in late 2008 which was one of the first clinical studies investigating an autologous T-cell therapy in MS patients. Data from this clinical study show evidence that Relapsing Remitting MS (RRMS) patients treated with Tovaxin saw overall clinical and disability benefits over the placebo group, including a clinically relevant decrease in the Annualized Relapse Rate (ARR), and improvement in disability score (EDSS), as well as an excellent safety profile with no serious adverse events related to Tovaxin treatment.

For more information visit the Opexa Therapeutics website at [ www.opexatherapeutics.com ].